Drugs / 25-Hydroxyvitamin D3
25-Hydroxyvitamin D3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04386850 | Apr → Nov 2020 | COVID-19 | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT02802449 Comparator | Sep 2013 → Mar 2016 | vitamin D deficiency | Charles Drew University of Medicine and Science | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-05-31 | Daiichi Sankyo | Daiichi Sankyo Launches Denotas® Chewable Combination Tablets with Calcium/Natural Vitamin D3/Magnesium daiichisankyo.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 25 hydroxy-Vitamin D3 | “two 50,000 IU tablets of oral Vitamin D3 \[also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3\]” NCT02802449 ↗ |
| Known as | 25 (OH) D3 | “two 50,000 IU tablets of oral Vitamin D3 \[also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3\]” NCT02802449 ↗ |
| Known as | cholecalciferol | “two 50,000 IU tablets of oral Vitamin D3 \[also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3\]” NCT02802449 ↗ |
| Known as | Vitamin D3 | “Vitamin D3” NCT02802449 ↗ |
| Route | Oral | “two 50,000 IU tablets of oral Vitamin D3” NCT02802449 ↗ |